Pharming Group N.V. Files 6-K with Press Release

Ticker: PHAR · Form: 6-K · Filed: 2025-05-08T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, press-release

TL;DR

Pharming Group N.V. dropped a 6-K with a press release on May 8, 2025. Check it for updates.

AI Summary

Pharming Group N.V. filed a Form 6-K on May 8, 2025, to furnish a press release dated May 8, 2025. The filing itself does not contain specific financial figures or operational updates beyond referencing the attached press release.

Why It Matters

This filing indicates that Pharming Group N.V. is providing updated information to the SEC, likely containing important business developments or financial results that investors should review.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of a press release and does not contain inherently risky information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to furnish a press release dated May 8, 2025, as required by SEC regulations for foreign private issuers.

What is the filing date of this Form 6-K?

The Form 6-K was filed as of May 8, 2025.

What is the exact name of the company filing this report?

The exact name of the company is Pharming Group N.V.

What exhibit is attached to this Form 6-K?

Exhibit 99.1, a press release of Pharming Group N.V. dated May 8, 2025, is furnished as part of this Report on Form 6-K.

Does Pharming Group N.V. file annual reports under Form 20-F or 40-F?

Pharming Group N.V. files annual reports under cover of Form 20-F.

From the Filing

0001828316-25-000027.txt : 20250508 0001828316-25-000027.hdr.sgml : 20250508 20250508065948 ACCESSION NUMBER: 0001828316-25-000027 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250508 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 25923757 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2025q1pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated May 8, 2025. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports first quarter 2025 financial results and provides business update SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: May 8, 2025 2 Pharming Group reports first quarter 2025 financial results and provides business update • First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 • RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE market • Joenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quarters • Operating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024 • Launched Joenja® (leniolisib) in England and Wales in April and preparing to file for U.S. FDA approval for pediatrics in the third quarter 2025 • Completed the acquisition of Abliva AB during the quarter and, in April, promptly started the second wave of recruitment for the pivotal FALCON clinical trial in mitochondrial DNA-driven primary mitochondrial diseases • 2025 total revenue guidance raised to US$325 - US$340 million, up from prior US$315 - US$335 million • Announces that Jeroen Wakkerman, Chief Financial Officer, will leave Pharming at the end of the month, to pursue other opportunities • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, May 8, 2025&#5

View on Read The Filing